Why Beam Therapeutics Stock Dipped Today
Beam Therapeutics (NASDAQ: BEAM), a pre-clinical gene-editing company, saw its shares dip by as much as 9.8% in early morning trading Monday. Ahead of the opening bell, Beam announced that the Food and Drug Administration (FDA) placed a clinical hold on its relapsed/refractory T-cell acute lymphoblastic leukemia candidate known as BEAM-201. Beam didn't provide a reason for the clinical hold in its early morning press release.